 (CFATF) Stock, Quote.Headers.trade-ideas

<p>Morgan Stanley  analyst Brian Nowak   maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $600 to $660.</p>


News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Meta Platforms, Raises Price Target to $660

<p>Morgan Stanley  analyst Nathan Feather   maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Equal-Weight and raises the price target from $31 to $32.</p>


MTCH

Morgan Stanley Maintains Equal-Weight on Match Group, Raises Price Target to $32

<p>Citigroup  analyst Andrew Kaplowitz   maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy and lowers the price target from $148 to $147.</p>


Citigroup Maintains Buy on Xylem, Lowers Price Target to $147

<p>Morgan Stanley  analyst Vincent Andrews   maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Overweight and lowers the price target from $110 to $90.</p>


Morgan Stanley Maintains Overweight on LyondellBasell Industries, Lowers Price Target to $90

<p>Streaming giant <strong>Netflix Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) gets a price target increase and call for a subscriber beat ahead of <a href="https://www.benzinga.com/general/sports/25/01/42882919/netflix-q4-to-show-advertising-live-sports-strength-analyst-says-multiyear-narrative-of-compounded-growth">fourth-quarter financial results.</a></p>
<p><strong>The Netflix Analyst: </strong>Macquarie analyst<strong> Tim Nollen</strong> reiterated an Outperform rating on Netflix and raised the price target from $795 to $965.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/24/12/42751367/netflix-posts-record-debut-with-squid-game-season-2-heres-how-many-people-watched-show">Netflix Posts Record Debut With &#8216;Squid Game&#8217; Season 2: Here&#8217;s How Many People Watched Show</a></strong></p>
<p><strong>The Analyst Takeaways:</strong> Live sports and several highly anticipated content releases in the fourth quarter could lead to a strong subscriber figure, Nollen said in a new investor note.</p>
<p>"We estimate Netflix will finish 2024 with more than 33m sub adds globally, totaling 293m, and there is a decent chance it beats this given the popularity of the Paul/Tyson fight, two NFL Christmas games and the Squid Game 2 release," Nollen said.</p>
<p>The analyst reminds investors this is the last quarter Netflix will provide subscriber figures and highlights the key areas to watch going forward.</p>
<p>"The focus now shifts to better monetizing the ad tier, with likely live sports expansion and price increases boosting revenue and earnings."</p>
<p>Nollen estimates that advertising revenue will be $2 billion in 2025, $3 billion in 2026 and $4.5 billion in 2027. Price increases for the U.S. standard plan could also add around $600 million in annualized revenue each year.</p>
<p>In the report, Nollen dives into live events as a key driver for Netflix subscriber growth and retention and also for advertising growth.</p>
<p>Nollen estimates Netflix made money on the NFL Christmas games, the WWE contract and<a href="https://www.benzinga.com/general/sports/24/12/42628116/netflix-adds-womens-world-cup-media-rights-from-football-to-futbol-streamer-all-in-on-live-sports"> future Women's World Cups</a>. The streamer could also bid on MLB and NFL rights as early as 2028.</p>
<p>"Netflix's current growth drivers set up a long-term runway for dominance in streaming."</p>
<p>Nollen highlights advertising tier growth, live events, upcoming price increases and intelligent content spending as the four keys to the Netflix story going forward.</p>
<p>On the subject of price increases, Nollen says Netflix's standard ad-free plan is less expensive than competitors like Max, Disney+, Hulu and Prime and has the most engagement, meaning churn could stay low with a higher monthly rate.</p>
<p>After landing rights to NFL games, the Tyson/Paul fight and WWE, Nollen doesn't think Netflix will slow down in its efforts to add live events.</p>
<p>"We expect Netflix to continue to acquire premium live content that will drive subscriber growth and retention, and importantly boost ad revenue."</p>
<p>Nollen said Netflix's push into live events could force pay TV subscribers out of the market.</p>
<p>"We expect events like the Christmas Day games and weekly WWE to put Netflix in a competitive position to gain more rights as it can distribute and monetize globally."</p>
<p><strong>NFLX Price Action:</strong> Netflix stock trades at $839.41 on Monday at publication versus a 52-week trading range of $475.26 to $941.75. Netflix stock is up 74% over the last year.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/entertainment/24/12/42563662/streamers-max-paramount-won-november-heres-why-analyst-expects-netflix-amazon-to-win-december">Streamers Max, Paramount+ Won November: Here&#8217;s Why Analyst Expects Netflix, Amazon To Win December</a></strong></li>
</ul>
<p><em>Photo: Courtesy Netflix</em></p>


Analyst Color

Entertainment

Reiteration

Media

Trading Ideas

NFLX

Netflix Stock Has 'Long Term Runway For Dominance In Streaming': Analyst Highlights 4 Key Catalysts

<p>Citigroup  analyst Andrew Kaplowitz   maintains Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) with a Buy and lowers the price target from $46 to $44.</p>


Citigroup Maintains Buy on Vontier, Lowers Price Target to $44

<p>On Sunday, <strong>Exact Sciences Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.74 billion</a>.</p>
<p>For 2024, the company expects screening revenue of $2.104 billion, up 13%, and Precision Oncology revenue of $655 million, up 4%.</p>
<p>The cancer detection company expects fourth-quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, compared to the consensus of $694.80 million.</p>
<p>The preliminary sales include screening revenue of $553 million and Precision Oncology revenue of $161 million.</p>
<p>The company plans to launch three new <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42936301/exact-sciences-announces-preliminary-fourth-quarter-2024-results" rel="noreferrer noopener">cancer tests in 2025</a>:</p>
<ul>
<li>Cologuard Plus, next-generation colorectal cancer screening test.</li>
<li>Oncodetect, a molecular residual disease test.</li>
<li>Cancerguard, multi-cancer screening test.</li>
</ul>
<p><strong>Goldman Sachs</strong> analyst Matthew Sykes highlights colorectal cancer (CRC) screening and multi-cancer early detection (MCED) as key risk areas in a competitive market.</p>
<p>The analyst writes that Exact Sciences stands out due to its established business and the higher accuracy of its stool-based DNA test compared to blood-based alternatives. However, the company's MCED test is still years away from being market-ready.</p>
<p>Sykes believes success in CRC screening could provide Exact Sciences with a major research and development edge, enabling a faster MCED launch thanks to its experienced team and existing infrastructure. On the other hand, failing to launch an MCED test within 3-4 years could undermine the firm's investment outlook.</p>
<p><strong>William Blair</strong> analyst Andrew Brackmann suggests that even a slight revenue beat, like this one, is unlikely to shift sentiment in the short term. Key updates on Cologuard's 2025 reacceleration and progress toward profitability likely won't surface until after the first quarter.</p>
<p>Brackmann anticipates this will remain the case but looks forward to insights on 2025 expectations and new product launches, including the company's MCED test, set to debut this year.</p>
<p>The long-term outlook remains strong, with shares trading at an attractive 4.1 times 2025 revenue. William Blair maintains <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">its Outperform rating</a>.</p>
<p><strong>Price Action: </strong>EXAS stock is down 1.61% at $55.59 at the last check on Monday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/42953261/nvidia-broadcom-and-marvell-positioned-for-growth-as-ai-demand-drives-semiconductor-momentum" target="_blank" rel="noreferrer noopener">Nvidia, Broadcom, Marvell Positioned For Growth As AI Demand Drives Semiconductor Momentum</a></strong></li>
</ul>


Earnings

Guidance

Health Care

General

EXAS

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market

<p>Morgan Stanley  analyst Elizabeth Porter   maintains LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) with a Underweight and raises the price target from $7 to $8.</p>


Morgan Stanley Maintains Underweight on LegalZoom.com, Raises Price Target to $8

<p>Citigroup  analyst Andrew Kaplowitz   maintains Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) with a Neutral and lowers the price target from $118 to $116.</p>


VLTO

Citigroup Maintains Neutral on Veralto, Lowers Price Target to $116

<p>Morgan Stanley  analyst Elizabeth Porter   maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Equal-Weight and raises the price target from $38 to $47.</p>


KVYO

Morgan Stanley Maintains Equal-Weight on Klaviyo, Raises Price Target to $47

<p>Morgan Stanley  analyst Brian Nowak   maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Equal-Weight and raises the price target from $41 to $44.</p>


CART

Morgan Stanley Maintains Equal-Weight on Maplebear, Raises Price Target to $44

AMZN

BIZD

LDOS

CNBC Halftime Report Final Trades: Leidos Holdings, JP Morgan Chase & Co., Amazon, VanEck BDC Income ETF

<p>Huntsman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Huntsman and provided 12-month price targets. The average target is $21.33, accompanied by a high estimate of $25.00 and a low estimate of $19.00. This current average represents a 9.89% decrease from the previous average price target of $23.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736791248_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Huntsman. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kieran De Brun</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Huntsman. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Huntsman compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Huntsman's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Huntsman's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HUN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Huntsman analyst ratings.</strong></a></p>
<h2>About Huntsman</h2>
<p>Huntsman Corp is a us-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. It derives most of its revenue from the Polyurethanes segment which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States &amp; Canada, Europe, Asia-Pacific, and the Rest of the world.</p>
<h3>Huntsman: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Huntsman's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>2.26%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Huntsman's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-2.14%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Huntsman's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-1.06%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Huntsman's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.45%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Huntsman's debt-to-equity ratio is below the industry average. With a ratio of <b>0.73</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Huntsman's Future

<p>Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $51.92, a high estimate of $91.00, and a low estimate of $14.00. Observing a downward trend, the current average is 14.77% lower than the prior average price target of $60.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736791242_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Intellia Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Jack Allen</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intellia Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Intellia Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intellia Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTLA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intellia Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Intellia Therapeutics</h2>
<p>Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.</p>
<h3>Intellia Therapeutics: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Intellia Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-24.02%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Intellia Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-1489.54%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Intellia Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-14.04%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Intellia Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-11.48%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Intellia Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.11</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTLA

13 Analysts Have This To Say About Intellia Therapeutics

<p>Morgan Stanley  analyst Tejas Savant   maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and lowers the price target from $156 to $150.</p>


ILMN

Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $150

<p>Analysts' ratings for Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.5, a high estimate of $55.00, and a low estimate of $45.00. This current average has increased by 11.96% from the previous average price target of $46.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736791234_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Skyward Specialty is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Skyward Specialty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Skyward Specialty compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Skyward Specialty's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Skyward Specialty's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SKWD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Skyward Specialty analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Skyward Specialty</h2>
<p>Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.</p>
<h3>A Deep Dive into Skyward Specialty's Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Skyward Specialty showcased positive performance, achieving a revenue growth rate of <strong>26.25%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Skyward Specialty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>12.14%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Skyward Specialty's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.82%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Skyward Specialty's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.04%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.15</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SKWD

Assessing Skyward Specialty: Insights From 4 Financial Analysts

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>ARM Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ARM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 29 uncommon options trades for ARM Holdings.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.</p>
<p>Out of all of the special options we uncovered, 15 are puts, for a total amount of $599,295, and 14 are calls, for a total amount of $1,106,775.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $180.0 for ARM Holdings over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for ARM Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ARM Holdings's whale activity within a strike price range from $70.0 to $180.0 in the last 30 days. </p>
<h3>ARM Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736791229_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$48.2</td>
<td>$46.95</td>
<td>$47.3</td>
<td>$105.00</td>
<td>$473.0K</td>
<td align="right">14</td>
<td align="right">100</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$37.25</td>
<td>$35.65</td>
<td>$36.78</td>
<td>$100.00</td>
<td>$110.3K</td>
<td align="right">904</td>
<td align="right">30</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.6</td>
<td>$11.55</td>
<td>$11.56</td>
<td>$110.00</td>
<td>$99.2K</td>
<td align="right">2</td>
<td align="right">563</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$25.1</td>
<td>$24.9</td>
<td>$24.9</td>
<td>$115.00</td>
<td>$67.2K</td>
<td align="right">122</td>
<td align="right">27</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$15.5</td>
<td>$15.4</td>
<td>$15.4</td>
<td>$135.00</td>
<td>$61.6K</td>
<td align="right">319</td>
<td align="right">58</td>
</tr>
</tbody>
</table>
</p>
<h3>About ARM Holdings</h3>
<p>Arm Holdings is the IP owner and developer of the ARM architecture (ARM stands for Acorn RISC Machine), which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allows them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Off-the-shelf and architectural customers pay a royalty fee per chip shipped.</p>
<p>Having examined the options trading patterns of ARM Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of ARM Holdings</h3>
<ul>
<li>With a volume of 1,938,426, the price of ARM is down -3.03% at $136.23. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 23 days.</li>
</ul>
<h3>Professional Analyst Ratings for ARM Holdings</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $162.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on ARM Holdings, maintaining a target price of $162. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ARM Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

ARM Holdings Unusual Options Activity For January 13

<p>27 analysts have expressed a variety of opinions on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">18</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Trade Desk and provided 12-month price targets. The average target is $136.56, accompanied by a high estimate of $155.00 and a low estimate of $57.00. This upward trend is apparent, with the current average reflecting a 10.84% increase from the previous average price target of $123.20.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736791227_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Trade Desk by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$133.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Sell</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Dan Salmon</td>
<td>New Street Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Trade Desk. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Trade Desk compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Trade Desk's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Trade Desk's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TTD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Trade Desk analyst ratings.</strong></a></p>
<h2>About Trade Desk</h2>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<h3>Trade Desk's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Trade Desk displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>27.32%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Trade Desk's net margin is impressive, surpassing industry averages. With a net margin of <strong>14.99%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Trade Desk's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.74%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Trade Desk's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.77%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Trade Desk's debt-to-equity ratio is below the industry average. With a ratio of <b>0.11</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Trade Desk Stands With Analysts

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Elevance Health</strong>.</p>
<p>Looking at options history for Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 80% of the investors opened trades with bullish expectations and 0% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $384,928 and 5, calls, for a total amount of $173,590.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $290.0 and $390.0 for Elevance Health, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Elevance Health's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Elevance Health's substantial trades, within a strike price spectrum from $290.0 to $390.0 over the preceding 30 days.</p>
<h3>Elevance Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736791224_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$34.7</td>
<td>$33.1</td>
<td>$33.2</td>
<td>$390.00</td>
<td>$225.8K</td>
<td align="right">180</td>
<td align="right">68</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$63.5</td>
<td>$58.7</td>
<td>$62.05</td>
<td>$340.00</td>
<td>$62.0K</td>
<td align="right">25</td>
<td align="right">25</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.6</td>
<td>$7.8</td>
<td>$8.01</td>
<td>$360.00</td>
<td>$48.1K</td>
<td align="right">56</td>
<td align="right">62</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.3</td>
<td>$4.7</td>
<td>$4.8</td>
<td>$330.00</td>
<td>$46.0K</td>
<td align="right">72</td>
<td align="right">96</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.2</td>
<td>$5.6</td>
<td>$5.9</td>
<td>$290.00</td>
<td>$38.3K</td>
<td align="right">7</td>
<td align="right">198</td>
</tr>
</tbody>
</table>
</p>
<h3>About Elevance Health</h3>
<p>Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.</p>
<p>After a thorough review of the options trading surrounding Elevance Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Elevance Health</h3>
<ul>
<li>Trading volume stands at 969,108, with ELV's price up by 3.94%, positioned at $396.15.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 10 days.</li>
</ul>
<h3>What The Experts Say On Elevance Health</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $480.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Elevance Health, maintaining a target price of $480. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Elevance Health options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

A Closer Look at Elevance Health's Options Market Dynamics

<p>Citigroup  analyst Andrew Kaplowitz   maintains Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) with a Buy and lowers the price target from $478 to $476.</p>


Comments

(CFATF) Forecast

(CFATF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga